Nuo TherapeuticsAURX 33 Current Ratio is 1.11 as of Mar. 2026, which is 14% below its 10-year median of 1.29. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Nuo Therapeutics ranks worse than 82.37% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Nuo Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 1.11.
Nuo Therapeutics has a current ratio of 1.11. It generally indicates good short-term financial strength.
The historical rank and industry rank for Nuo Therapeutics's Current Ratio or its related term are showing as below:
AURX'
s Current Ratio Range Over the Past 10 Years
Min: 0.02 Med: 1.29 Max: 8.32
Current: 1.11
During the past 13 years, Nuo Therapeutics's highest Current Ratio was 8.32. The lowest was 0.02. And the median was 1.29.
AURX's Current Ratio is ranked worse than 82.37% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs AURX: 1.11
Nuo Therapeutics (OTCPK:AURX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Nuo Therapeutics Current Ratio Related Terms
Nuo Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Nuo Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AURX vs PDSB, LTRN, VERU: Current Ratio Comparison
For the Biotechnology subindustry, Nuo Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (AURX) has a Current Ratio of 1.11 as of Mar. 2026. This is 14% below median its historical median of 1.29. Over the past decade, Nuo Therapeutics' Current Ratio has ranged from 0.02 to 8.32. According to the industry distribution chart, Nuo Therapeutics ranks #1163 out of 1412 companies in the Biotechnology industry, placing it in the top 82.4%.
Is Nuo Therapeutics' Current Ratio too high?
Nuo Therapeutics' current Current Ratio of 1.11 is 14% below median its 10-year median of 1.29. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 8.32. The Biotechnology industry median Current Ratio is 3.89. Nuo Therapeutics' value of 1.11 is 71.5% below this industry median. Based on the distribution chart, Nuo Therapeutics ranks #1163 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Current Ratio compare to PDSB and LTRN?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #1163 out of 1412 companies for Current Ratio. This places Nuo Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.89. Nuo Therapeutics' value of 1.11 is 71.5% below this benchmark. Historically, Nuo Therapeutics' own Current Ratio has ranged from 0.02 to 8.32 over the past decade. While the company's 10-year median is 1.29 vs. the industry median of 3.89, Nuo Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuo Therapeutics's current Current Ratio of 1.11 is 71.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuo Therapeutics's current Current Ratio is 1.11, which is 14% below median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $1.01 — trading 76.1% below its estimated fair value. The current Current Ratio is 1.11, which is 14% below median its 10-year median of 1.29 and 71.5% below the Biotechnology industry median of 3.89. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Current Ratio is 1.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuo Therapeutics (AURX) Overvalued in 2026?
Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued.
The current stock price of $1.01 is trading 76.1% below its estimated GF Value™ of $4.23.
GuruFocus considers Nuo Therapeutics to be Possible Value Trap.
Key valuation signals for AURX:
Current Ratio: 1.11 (14% below median its 10-year median of 1.29)
GF Value™: $4.23 vs. price of $1.01 (76.1% below fair value)
Industry Position: 71.5% below the Biotechnology median (#1163 of 1412)
No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score
Get the complete analysis for AURX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 
